Osong Public Health and Research Perspectives

Commentary

Challenges in capacity building of national immunization programs and emergency or pandemic vaccination responses in the Global Health Security Agenda member countries: Sookhyun Lee, Jung Ju Oh, Sang Hyun Park, Dasol Ro, Ye Jin Jeong, So Yoon Kim; Osong Public Health Res Perspect. 2024;15(2):182-185. Published online March 28, 2024; DOI: https://doi.org/10.24171/j.phrp.2023.0159

1,741 View
163 Download

Graphical Abstract PDF

Brief Report

JYNNEOS vaccine safety monitoring in the Republic of Korea, 2022: a cross-sectional study: Jaeeun Lee, Seunghyun Lewis Kwon, Jinhee Park, Hyuna Bae, Hyerim Lee, Geun-Yong Kwon; Osong Public Health Res Perspect. 2023;14(5):433-438. Published online October 18, 2023; DOI: https://doi.org/10.24171/j.phrp.2023.0182

1,565 View
50 Download
4 Web of Science
3 Crossref

Graphical Abstract Abstract PDF

Objectives
With the recent global mpox outbreak, the JYNNEOS vaccine (Modified Vaccinia Ankara-Bavarian Nordic) was developed as a third-generation smallpox vaccine and initially favored for mpox immunization. Vaccine-associated side effects contribute to vaccine hesitancy. Consequently, tracking adverse events post-immunization is crucial for safety management. This study used data from the national active vaccine safety surveillance conducted in Korea from August 25 to November 24, 2022 to detect potential safety signals and adverse events. Methods: Data on health conditions following vaccination were gathered from web-based surveys and reported via active surveillance through the Immunization Registry Information System. This follow-up system functioned via a text message link, surveying adverse events and health conditions beginning on the second day post-vaccination. Information about specific adverse events, including both local and systemic reactions, was collected. Results: The study included 86 healthcare workers who had received at least 1 dose of the JYNNEOS vaccine. Among the respondents, 79.1% reported experiencing at least 1 adverse event, with the majority being local reactions at the injection site. The incidence of adverse events was higher following the first dose (67.9%) than after the second dose (34.4%). The most frequently reported adverse event for both doses was mild pain at the injection site. Conclusion: The study provides crucial information on the safety of the JYNNEOS vaccine, demonstrating that most adverse events were manageable and predominantly localized to the injection site. Nonetheless, additional research is needed on the safety of various vaccine administration techniques and the vaccine’s effects on broader demographics.

Citations

Citations to this article as recorded by

Adverse Reactions After Intradermal Vaccination With JYNNEOS for Mpox in Korea
So Yun Lim, Yu Mi Jung, Yeonjae Kim, Gayeon Kim, Jaehyun Jeon, BumSik Chin, Min-Kyung Kim
Journal of Korean Medical Science.2024;[Epub] CrossRef
First Nationwide Mpox Vaccination Program in the Republic of Korea: Implications for an Enhanced Public Health Response
Seunghyun Lewis Kwon, Minju Song, Wonkyung Lee, Jeeyeon Shin, Su-Yeon Lee, Sang-Gu Yeo, Minjeong Kim, Sanggyun Jeong, Joonku Park, Dongwoo Lee, Sookyoung Lim
Journal of Korean Medical Science.2024;[Epub] CrossRef
Global perspectives on smallpox vaccine against monkeypox: a comprehensive meta-analysis and systematic review of effectiveness, protection, safety and cross-immunogenicity
Hao Liu, Wenjing Wang, Yang Zhang, Fuchun Wang, Junyi Duan, Tao Huang, Xiaojie Huang, Tong Zhang
Emerging Microbes & Infections.2024;[Epub] CrossRef

Original Articles

Estimating the number of severe COVID-19 cases and COVID-19-related deaths averted by a nationwide vaccination campaign in Republic of Korea: Ji Hae Hwang, Ju Hee Lee, Eun Jung Jang, Ryu Kyung Kim, Kil Hun Lee, Seon Kyeong Park, Sang Eun Lee, Chungman Chae, Sangwon Lee, Young Joon Park; Osong Public Health Res Perspect. 2023;14(3):164-172. Published online June 22, 2023; DOI: https://doi.org/10.24171/j.phrp.2023.0096

2,490 View
133 Download
2 Web of Science
3 Crossref

Graphical Abstract Abstract PDF

Objectives
The Korea Disease Control and Prevention Agency promotes vaccination by regularly providing information on its benefits for reducing the severity of coronavirus disease 2019 (COVID-19). This study aimed to analyze the number of averted severe COVID-19 cases and COVID-19-related deaths by age group and quantify the impact of Republic of Korea’s nationwide vaccination campaign.
Methods
We analyzed an integrated database from the beginning of the vaccination campaign on February 26, 2021 to October 15, 2022. We estimated the cumulative number of severe cases and COVID-19-related deaths over time by comparing observed and estimated cases among unvaccinated and vaccinated groups using statistical modeling. We compared daily age-adjusted rates of severe cases and deaths in the unvaccinated group to those in the vaccinated group and calculated the susceptible population and proportion of vaccinated people by age.
Results
There were 23,793 severe cases and 25,441 deaths related to COVID-19. We estimated that 119,579 (95% confidence interval [CI], 118,901–120,257) severe COVID-19 cases and 137,636 (95% CI, 136,909–138,363) COVID-19-related deaths would have occurred if vaccination had not been performed. Therefore, 95,786 (95% CI, 94,659–96,913) severe cases and 112,195 (95% CI, 110,870–113,520) deaths were prevented as a result of the vaccination campaign.
Conclusion
We found that, if the nationwide COVID-19 vaccination campaign had not been implemented, the number of severe cases and deaths would have been at least 4 times higher. These findings suggest that Republic of Korea’s nationwide vaccination campaign reduced the number of severe cases and COVID-19 deaths.

Citations

Citations to this article as recorded by

Assessing the determinants of influenza and COVID-19 vaccine co-administration decisions in the elderly
Seunghyun Lewis Kwon, So-Yeon Kim, Minju Song, Hyung-Min Lee, Seon-Hwa Ban, Mi-Soon Lee, Hyesun Jeong
Human Vaccines & Immunotherapeutics.2024;[Epub] CrossRef
코로나바이러스감염증-19 대조 백신 및 연구용 백신 지원
수봉 채, 미미소 이, 은영 조, 준구 박
Public Health Weekly Report.2024; 17(32): 1378. CrossRef
Comparative Effectiveness of COVID-19 Bivalent Versus Monovalent mRNA Vaccines in the Early Stage of Bivalent Vaccination in Korea: October 2022 to January 2023
Ryu Kyung Kim, Young June Choe, Eun Jung Jang, Chungman Chae, Ji Hae Hwang, Kil Hun Lee, Ji Ae Shim, Geun-Yong Kwon, Jae Young Lee, Young-Joon Park, Sang Won Lee, Donghyok Kwon
Journal of Korean Medical Science.2023;[Epub] CrossRef

Quality of life in patients treated for COVID-19–associated mucormycosis at a tertiary care hospital: Pragya Kumar, Rajath Rao UR, Nilanjan Roy, Deepika Agrawal, Shamshad Ahmad, Kranti Bhavana; Osong Public Health Res Perspect. 2023;14(2):119-128. Published online April 18, 2023; DOI: https://doi.org/10.24171/j.phrp.2022.0307

2,667 View
67 Download
1 Web of Science
1 Crossref

Graphical Abstract Abstract PDF

Objectives
Coronavirus disease 2019 (COVID-19)–associated mucormycosis (CAM) has emerged as a formidable infection in patients with COVID-19. The aggressive management of CAM affects quality of life (QOL); thus, this study was designed to assess the QOL in patients with CAM at a tertiary healthcare institution.
Methods
This cross-sectional study of 57 patients with CAM was conducted over 6 months using a semi-structured standard questionnaire (the abbreviated World Health Organization Quality of Life questionnaire [WHO-BREF]) and a self-rated improvement (SRI) scale ranging from 0 to 9. Cut-off values of ≤52 and <7 were considered to indicate poor QOL and poor improvement, respectively. The correlations of QOL and SRI scores were evaluated using Spearman rho values.
Results
In total, 27 patients (47.4%; 95% confidence interval [CI], 34.9%–60.1%) and 26 patients (45.6%; 95% CI, 33.4%–58.4%) had poor QOL and poor SRI scores, respectively. The overall median (interquartile range) QOL score was 52 (41–63). Headache (adjusted B, −12.3), localized facial puffiness (adjusted B , −16.4), facial discoloration (adjusted B, −23.4), loosening of teeth (adjusted B, −18.7), and facial palsy (adjusted B, −38.5) wer e significantly associated with the QOL score in patients with CAM.
Conclusion
Approximately 1 in 2 patients with CAM had poor QOL and poor improvement. Various CAM symptoms were associated with QOL in these patients. Early recognition is the key to optimal treatment, improved outcomes, and improved QOL in patients with CAM.

Citations

Citations to this article as recorded by

WHO BREF Quality of Life Score as a Prognostic Indicator of Survival in Patients recovered from COVID-19 Associated Rhino-Orbito-Cerebral Mucormycosis
K. Nidhin Das, Vidhu Sharma, Vishudh Mohan, Kapil Soni, Ankita Chugh, Bikram Choudhury, Amit Goyal
Indian Journal of Otolaryngology and Head & Neck S.2024; 76(4): 3441. CrossRef

Vaccine hesitancy in patients with COVID-19 who have back pain: Askeri Türken, Haşim Çapar; Osong Public Health Res Perspect. 2023;14(2):100-109. Published online March 24, 2023; DOI: https://doi.org/10.24171/j.phrp.2023.0003

2,665 View
80 Download
1 Crossref

Graphical Abstract Abstract PDF

Objectives
Musculoskeletal pain is among the most common symptoms in patients diagnosed with coronavirus disease 2019 (COVID-19), and it has placed a significant burden on health worldwide during the pandemic. This study explored vaccine hesitancy and associated factors in patients with positive COVID-19 polymerase chain reaction test results who were hospitalized and had back pain.
Methods
A cross-sectional study was conducted among 170 hospitalized COVID-19 patients over 18 years of age. Data were analyzed using descriptive statistics with IBM SPSS ver. 25.0.
Results
COVID-19 patients who were married considered COVID-19 vaccinations riskier than unmarried COVID-19 patients. Patients who had not been vaccinated expressed higher levels of distrust towards COVID-19 vaccines than patients who had been vaccinated. Participants had relatively little hesitation toward the Sinovac vaccine. High vaccine confidence was found in all participants regardless of vaccination status. Those who had not received the COVID-19 vaccine reported higher risk perceptions than those who had received at least 1 dose of any COVID-19 vaccine.
Conclusion
Measurements of the hesitancy of vaccinated and non-vaccinated patients or members of society towards vaccines can be an important parameter for health authorities to find solutions.

Citations

Citations to this article as recorded by

COVID-19 VE DAVRANIŞSAL İKTİSAT: KÜRESEL BİR PANDEMİ SIRASINDA İNSAN DAVRANIŞINI ANLAMAK
İlknur ARSLAN ARAS
Sağlık ve Sosyal Refah Araştırmaları Dergisi.2024; 6(1): 97. CrossRef

Association between face covering policies and the incidence of coronavirus disease 2019 in European countries: Sookhyun Kim, Jiyoung Oh, Sangwoo Tak; Osong Public Health Res Perspect. 2023;14(1):31-39. Published online February 1, 2023; DOI: https://doi.org/10.24171/j.phrp.2022.0287

2,710 View
83 Download
1 Web of Science
1 Crossref

Graphical Abstract Abstract PDF

Objectives
This study was conducted to determine the impact of the strengthening or relaxation of face covering mandates on the subsequent national case incidence of coronavirus disease 2019 (COVID-19) in Europe as the full vaccination rate was increasing.
Methods
European countries in which case incidence increased for 3 consecutive weeks were monitored and analyzed using COVID-19 incidence data shared by the World Health Organization (WHO). The epidemic trend of COVID-19 in Europe was compared with that of countries elsewhere in the world based on WHO weekly epidemiological reports from June 20 to October 30, 2021. In addition, this study provided insight into the impact of government mask mandates on COVID-19 incidence in Europe by measuring the index scores of those facial covering policies before and after mandate relaxation or strengthening. The effects of the vaccination rate and the speed of vaccination on COVID-19 incidence were also analyzed.
Results
The incidence of COVID-19 after the relaxation of face covering mandates was significantly higher than before relaxation. However, no significant difference was observed in vaccination rate between countries with increased and decreased incidence. Instead, rapid vaccination delayed the resurgence in incidence.
Conclusion
The findings suggest that face covering policies in conjunction with rapid vaccination efforts are essential to help mitigate the spread of COVID-19.

Citations

Citations to this article as recorded by

Non-pharmaceutical interventions in containing COVID-19 pandemic after the roll-out of coronavirus vaccines: a systematic review
Xiaona He, Huiting Chen, Xinyu Zhu, Wei Gao
BMC Public Health.2024;[Epub] CrossRef

Brief Report

Adverse events of the Pfizer-BioNTech COVID-19 vaccine in Korean children and adolescents aged 5 to 17 years: Seontae Kim, Yeseul Heo, Soon-Young Seo, Do Sang Lim, Enhi Cho, Yeon-Kyeng Lee; Osong Public Health Res Perspect. 2022;13(5):382-390. Published online October 14, 2022; DOI: https://doi.org/10.24171/j.phrp.2022.0233

2,987 View
120 Download
1 Web of Science
3 Crossref

Abstract PDF

Objectives
This study aimed to identify potential safety signals and adverse events following the primary Pfizer-BioNTech coronavirus disease 2019 (COVID-19) vaccination series among children and adolescents aged 5 to 17 years in the Republic of Korea. Methods: Adverse events reported through the COVID-19 vaccination management system (CVMS, a web-based passive vaccine safety surveillance system) and adverse events and health conditions collected from a text message-based survey were analyzed. Results: A total of 14,786 adverse events among 5 to 17-year-old children and adolescents were reported in the CVMS; 14,334 (96.9%) were non-serious and 452 (3.1%) were serious, including 125 suspected cases of acute cardiovascular injury and 101 suspected cases of anaphylaxis. The overall reporting rate was lower in 5 to 11-year-old children (64.5 per 100,000 doses) than in 12 to 17-year-old adolescents (300.5 per 100,000 doses). The text message survey identified that local and systemic adverse events after either dose were reported less frequently in 5 to 11-year-old children than in 12 to 17-year-old adolescents (p<0.001). The most commonly reported adverse events were pain at the injection site, myalgia, headache, and fatigue/tiredness. Conclusion: The overall results are consistent with the results of controlled trials; serious adverse events were extremely rare among 5 to 17-year-old children and adolescents following Pfizer-BioNTech COVID-19 vaccination. Adverse events were less frequent in children aged 5 to 11 years than in adolescents aged 12 to 17 years.

Citations

Citations to this article as recorded by

The descriptive epidemiology of adverse events following two doses of mRNA COVID-19 vaccination in Curaçao, the Caribbean
Jonathan Lambo, Sirving Keli, Shaheen Khan Kaplan, Temiloluwa Njideaka-Kevin, Sireesha Bala Arja, Alaa Khedir Omer Altahir, Itunu Olonade, Rohit Kumar
Infectious Diseases.2024; : 1. CrossRef
Safety monitoring of COVID-19 vaccines: February 26, 2021, To June 4, 2022, Republic of Korea
Yeon-Kyeng Lee, Yunhyung Kwon, Yesul Heo, Eun Kyoung Kim, Seung Yun Kim, Hoon Cho, Seontae Kim, Mijeong Ko, Dosang Lim, Soon-Young Seo, Enhi Cho
Clinical and Experimental Pediatrics.2023; 66(10): 415. CrossRef
Effectiveness of the BNT162b2 vaccine in preventing morbidity and mortality associated with COVID-19 in children aged 5 to 11 years: A systematic review and meta-analysis
Sumayyah Ebrahim, Ntombifuthi Blose, Natasha Gloeck, Ameer Hohlfeld, Yusentha Balakrishna, Rudzani Muloiwa, Andy Gray, Andy Parrish, Karen Cohen, Ruth Lancaster, Tamara Kredo, Julia Robinson
PLOS Global Public Health.2023; 3(12): e0002676. CrossRef

Review Article

India’s efforts to achieve 1.5 billion COVID-19 vaccinations: a narrative review: Kapil Singh, Ashwani Verma, Monisha Lakshminarayan; Osong Public Health Res Perspect. 2022;13(5):316-327. Published online October 14, 2022; DOI: https://doi.org/10.24171/j.phrp.2022.0104

5,537 View
108 Download
9 Web of Science
13 Crossref

Graphical Abstract Abstract PDF

The initial case of coronavirus disease 2019 (COVID-19) in India was reported on January 30, 2020, and subsequently, the number of COVID-19-infected patients surged during the first wave of April 2020 and the second wave in the same month of 2021. The government of India imposed a strict nationwide lockdown in April 2020 and extended it until May 2020. The second wave of COVID-19 in India overwhelmed the country’s health facilities and exhausted its medical and paramedical workforce. This narrative review was conducted with the aim of summarizing the evidence drawn from policy documents of governmental and non-governmental organizations, as well as capturing India's COVID-19 vaccination efforts. The findings from this review cover the Indian government's vaccination initiatives, which ranged from steps taken to combat vaccine hesitancy to vaccination roadmaps, deployment plans, the use of digital health technology, vaccination monitoring, adverse effects, and innovative strategies such as Har Ghar Dastak and Jan Bhagidari Andolan (people’s participation). These efforts collectively culminated in the successful administration of more than 1.8 billion doses of COVID-19 vaccines in India. This review also provides insights into other countries’ responses to COVID-19 and guidance for future pandemics.

Citations

Citations to this article as recorded by

Developments and Trends of Immunization in India: A Narrative Review
Pratik P Tawde, Zahiruddin Quazi, Abhay Gaidhane, Sonali G Choudhari
Cureus.2024;[Epub] CrossRef
Digital health technology used in emergency large-scale vaccination campaigns in low- and middle-income countries: a narrative review for improved pandemic preparedness
Paula Mc Kenna, Lindsay A. Broadfield, Annik Willems, Serge Masyn, Theresa Pattery, Ruxandra Draghia-Akli
Expert Review of Vaccines.2023; 22(1): 243. CrossRef
Media Reporting Relating to COVID-19 Vaccination as a Driver of Vaccine Hesitancy Prior to the Second Wave of the COVID-19 Pandemic in India: A Content Analysis of Newspaper and Digital Media Reports
Saurav Basu, Himanshi Sharma
Cureus.2023;[Epub] CrossRef
An assessment of the strategy and status of COVID-19 vaccination in India
Sneh Lata Gupta, Surbhi Goswami, Ananya Anand, Namrata Naman, Priya Kumari, Priyanka Sharma, Rishi K. Jaiswal
Immunologic Research.2023; 71(4): 565. CrossRef
Development of a Choice-framework for Covid vaccines in India using a multi-criteria decision analysis approach
Tarun K. George, Nayana P. Nair, Awnish Kumar Singh, A. Dilesh Kumar, Arup Deb Roy, Varshini Neethi Mohan, Gagandeep Kang
Vaccine.2023; 41(25): 3755. CrossRef
COVID-19 Booster Dose Coverage and Hesitancy among Older Adults in an Urban Slum and Resettlement Colony in Delhi, India
Nandini Sharma, Saurav Basu, Heena Lalwani, Shivani Rao, Mansi Malik, Sandeep Garg, Rahul Shrivastava, Mongjam Meghachandra Singh
Vaccines.2023; 11(7): 1177. CrossRef
Review of the unmet medical need for vaccination in adults with immunocompromising conditions: An Indian perspective
Ashok Vaid, Neha Rastogi, T. Mark Doherty, Peter San Martin, Yashpal Chugh
Human Vaccines & Immunotherapeutics.2023;[Epub] CrossRef
Translating the COVID-19 experience in widening the HPV vaccination campaign for cervical cancer in India
Aruni Ghose, Anisha Agarwal, Bhawna Sirohi, Shona Nag, Linus Chuang, Swarupa Mitra
Gynecologic Oncology Reports.2023; 48: 101247. CrossRef
Symptomatic prevalence of covid-19 in vaccinated and non-vaccinated population
Jay Bhupesh Pandya, Nirali Milind Shethia, Divya Bangera, Shailaja Gada Saxena
IP International Journal of Medical Microbiology a.2023; 9(2): 110. CrossRef
Active surveillance of adverse events following COVID-19 vaccines in a tertiary care hospital
Naveena Mary Cherian, Dravya Anna Durai, Muhammed Jaisel, Divyansh Sharma, Juny Sebastian, Chetak Kadabasal Basavaraja, Merrin Mathew
Therapeutic Advances in Vaccines and Immunotherapy.2023;[Epub] CrossRef
Effectiveness of ayurvedic formulation, NAOQ19 along with standard care in the treatment of mild-moderate COVID-19 patients: A double blind, randomized, placebo-controlled, multicentric trial
Pankaj Bhardwaj, Kalaiselvan Ganapathy, Monika Pathania, K.H. Naveen, Jaykaran Charan, Siddhartha Dutta, Ravisekhar Gadepalli, Srikanth Srinivasan, Manoj Kumar Gupta, Akhil D. Goel, Naresh Midha, Bharat Kumar, Meenakshi Sharma, Praveen Sharma, Mithu Baner
Journal of Ayurveda and Integrative Medicine.2023; 14(6): 100778. CrossRef
Balancing Routine and Pandemic: The Synergy of India’s Universal Immunization Program and COVID-19 Vaccination Program
Pawan Kumar, Ashish Birendra Chakraborty, Suhas Dhandore, Pritu Dhalaria, Ajeet Kumar Singh, Disha Agarwal, Kapil Singh, Pretty Priyadarshini, Paras Jain, Vidushi Bahl, Gunjan Taneja
Vaccines.2023; 11(12): 1776. CrossRef
Unveiling vaccine safety: a narrative review of pharmacovigilance in India's COVID-19 vaccination
Megha Hegde, Saurav Raj, Dhananjay Tikadar, Sanatkumar B Nyamagoud
Monaldi Archives for Chest Disease.2023;[Epub] CrossRef

Original Article

Characteristics of COVID-19 outbreaks and risk factors for transmission at an army training center in South Korea from June to August 2021: U Jin Cho, Seongjin Wang, Seonju Yi, Yeon Hwa Choi, Eun-Young Kim, Jin A Kim, Sanghwan Bae, Jungyeon Yu, Jangkyu Choi, Young-Joon Park; Osong Public Health Res Perspect. 2022;13(4):263-272. Published online July 27, 2022; DOI: https://doi.org/10.24171/j.phrp.2022.0149

3,735 View
122 Download
2 Web of Science
2 Crossref

Abstract PDF

Objectives
It is crucial to establish the characteristics of coronavirus disease 2019 (COVID-19) outbreaks at army training centers to develop preventive measures. Therefore, this study aimed to determine the COVID-19 transmission patterns and risk factors in a sequence of outbreaks at an army training center from June to August 2021.
Methods
This study included 1,324 trainees at an army training center where outbreaks occurred from June to August 2021. The outbreak was qualitatively analyzed according to the period, attack rate, demographic characteristics, vaccination history, and living areas. An aerodynamic experiment was performed to evaluate aerosol transmission in living areas.
Results
Three outbreaks occurred at the army training center from June to August 2021. The first, second, and third outbreaks lasted for 32, 17, and 24 days, and the attack rates were 12.8%, 18.1%, and 8.9%, respectively. Confirmed cases were distributed in all age groups. Recruits and the unvaccinated were at higher risk for COVID-19. The aerodynamic experiment verified the possibility of aerosol transmission within the same living area.
Conclusion
COVID-19 transmission at army training centers should be minimized through quarantine and post-admission testing during the latency period as part of integrated measures that include facility ventilation, vaccination, indoor mask-wearing, and social distancing.

Citations

Citations to this article as recorded by

COVID-19 outbreak in a religious village community in Republic of Korea and risk factors for transmission
Jiae Shim, Eunju Lee, Eunyoung Kim, Yeonhwa Choi, Giseok Kang, Bryan Inho Kim
Osong Public Health and Research Perspectives.2023; 14(2): 110. CrossRef
Epidemiological Characteristics of a COVID-19 Outbreak in a Psychiatric Hospital in Chung-buk
Se-Hyuk Jang, Young-Joon Park, Ji-Joo Lee, Woo-Jin Jung
Healthcare.2023; 11(16): 2332. CrossRef

Brief Report

Safety monitoring of COVID-19 vaccination among adolescents aged 12 to 17 years old in the Republic of Korea: Seontae Kim, Insob Hwang, Mijeong Ko, Yunhyung Kwon, Yeon-Kyeng Lee; Osong Public Health Res Perspect. 2022;13(3):230-237. Published online June 10, 2022; DOI: https://doi.org/10.24171/j.phrp.2022.0122

4,953 View
147 Download
9 Web of Science
10 Crossref

Graphical Abstract Abstract PDF

Objectives
This study aimed to disseminate information on coronavirus disease 2019 (COVID-19) vaccine safety among adolescents aged 12 to 17 years in the Republic of Korea. Methods: Two databases were used to assess COVID-19 vaccine safety in adolescents aged 12 to 17 years who completed the primary Pfizer-BioNTech vaccination series. Adverse events reported to the web-based COVID-19 vaccination management system (CVMS) and collected in the text message-based system were analyzed. Results: From March 5, 2021 to February 13, 2022, 12,216 adverse events among 12- to 17-yearolds were reported to the CVMS, of which 97.1% were non-serious adverse events and 2.9% were serious adverse events, including 85 suspected cases of anaphylaxis, 74 suspected cases of myocarditis and/or pericarditis, and 2 deaths. From December 13, 2021 to January 26, 2022, 10,389 adolescents responded to a text message survey, and local/systemic adverse events were more common after dose 2 than after dose 1. The most commonly reported events following either vaccine dose were pain at the injection site, headache, fatigue/tiredness, and myalgia. Conclusion: The overall results are consistent with previous findings; the great majority of adverse events were non-serious, and serious adverse events were rare among adolescents aged 12 to 17 years following Pfizer-BioNTech COVID-19 vaccination.

Citations

Citations to this article as recorded by

Suspected Myocarditis after mRNA COVID-19 Vaccination among South Korean Adolescents
Mi Jin Kim, Jin Hee Kim, Hyun Ok Jun, Kyung Min Kim, Min Sub Jeung, Jun Sung Park
Journal of Pediatric Infectious Diseases.2024; 19(02): 075. CrossRef
Characterization of Brighton Collaboration criteria for myocarditis and pericarditis following COVID-19 vaccine in Korean adolescents
Jue Seong Lee, HyoSug Choi, Seung Hwan Shin, Myung-Jae Hwang, Sara Na, Jong Hee Kim, Sangshin Park, Yoonsun Yoon, Hyun Mi Kang, Bin Ahn, Kyoungsan Seo, Young June Choe
Vaccine.2024; 42(14): 3333. CrossRef
Myopericarditis following COVID-19 vaccination in children: a systematic review and meta-analysis
Ashiley Annushri Thenpandiyan, Ryan Ruiyang Ling, Robert Grignani, Megan Ruien Ling, Arthena Anushka Thenpandiyan, Bee Choo Tai, Jyoti Somani, Kollengode Ramanathan, Swee Chye Quek
Singapore Medical Journal.2024;[Epub] CrossRef
Comparative safety of monovalent and bivalent mRNA COVID-19 booster vaccines in adolescents aged 12 to 17 years in the Republic of Korea
Mijeong Ko, Seontae Kim, Seok-Kyoung Choi, Seung Hwan Shin, Yeon-Kyeng Lee, Yunhyung Kwon
Osong Public Health and Research Perspectives.2024; 15(4): 364. CrossRef
Association of new onset seizure and COVID‐19 vaccines and long‐term follow‐up: A systematic review and meta‐analysis
Ali Rafati, Melika Jameie, Mobina Amanollahi, Yeganeh Pasebani, Nastaran Salimi, Mohammad Hosein Feyz Kazemi, Mana Jameie, Mohammad Yazdan Pasebani, Delaram Sakhaei, Fateme Feizollahi, Churl‐Su Kwon
Epilepsia.2024;[Epub] CrossRef
Immunogenicity, effectiveness, and safety of COVID-19 vaccines among children and adolescents aged 2–18 years: an updated systematic review and meta-analysis
Peng Gao, Liang-Yu Kang, Jue Liu, Min Liu
World Journal of Pediatrics.2023; 19(11): 1041. CrossRef
Incidence of myopericarditis after mRNA COVID-19 vaccination: A meta-analysis with focus on adolescents aged 12–17 years
Bao-Qiang Guo, Hong-Bin Li, Li-Qiang Yang
Vaccine.2023; 41(28): 4067. CrossRef
Safety monitoring of COVID-19 vaccines: February 26, 2021, To June 4, 2022, Republic of Korea
Yeon-Kyeng Lee, Yunhyung Kwon, Yesul Heo, Eun Kyoung Kim, Seung Yun Kim, Hoon Cho, Seontae Kim, Mijeong Ko, Dosang Lim, Soon-Young Seo, Enhi Cho
Clinical and Experimental Pediatrics.2023; 66(10): 415. CrossRef
Risk of Coronavirus Disease 2019 Messenger RNA Vaccination-Associated Myocarditis and Pericarditis – A Systematic Review of Population-Based Data
Yen-Ching Lin, Chia-Hsuin Chang, Wei-Ju Su, Chin-Hui Yang, Jann-Tay Wang
Risk Management and Healthcare Policy.2023; Volume 16: 2085. CrossRef
COVID-19 Vaccination in Korea: Past, Present, and the Way Forward
Eliel Nham, Joon Young Song, Ji Yun Noh, Hee Jin Cheong, Woo Joo Kim
Journal of Korean Medical Science.2022;[Epub] CrossRef

Original Articles

COVID-19 outbreak response at a nursing hospital in South Korea in the post-vaccination era, including an estimation of the effectiveness of the first shot of the Oxford-AstraZeneca COVID-19 vaccine (ChAdOx1-S): Chanhee Kim, Geon Kang, Sun Gu Kang, Heeyoung Lee; Osong Public Health Res Perspect. 2022;13(2):114-122. Published online April 26, 2022; DOI: https://doi.org/10.24171/j.phrp.2021.0262

4,995 View
97 Download
1 Web of Science
1 Crossref

Abstract PDF

Objectives
We descriptively reviewed a coronavirus disease 2019 (COVID-19) outbreak at a nursing hospital in Gyeonggi Province (South Korea) and assessed the effectiveness of the first dose of the Oxford-AstraZeneca vaccine in a real-world population. Methods: The general process of the epidemiological investigation included a public health intervention. The relative risk (RR) of vaccinated and unvaccinated groups was calculated and compared to confirm the risk of severe acute respiratory syndrome coronavirus-2 (SARSCoV-2) infection, and vaccine effectiveness was evaluated based on the calculated RR. Results: The population at risk was confined to ward E among 8 wards of Hospital X, where the outbreak occurred. This population comprised 55 people, including 39 patients, 12 nurses, and 4 caregivers, and 19 cases were identified. The RR between the vaccinated and unvaccinated groups was 0.04, resulting in a vaccine effectiveness of 95.3%. The vaccination rate of the nonpatients in ward E was the lowest in the entire hospital, whereas the overall vaccination rate of the combined patient and non-patient groups in ward E was the third lowest. Conclusion: The first dose of the Oxford-AstraZeneca vaccine (ChAdOx1-S) was effective in preventing SARS-CoV-2 infection. To prevent COVID-19 outbreaks in medical facilities, it is important to prioritize the vaccination of healthcare providers.

Citations

Citations to this article as recorded by

COVID-19 Vaccination in Korea: Past, Present, and the Way Forward
Eliel Nham, Joon Young Song, Ji Yun Noh, Hee Jin Cheong, Woo Joo Kim
Journal of Korean Medical Science.2022;[Epub] CrossRef

Limitations of immunization registers at community health centers for measuring immunization coverage: a case study of the Japanese encephalitis mass immunization program in Bali Province, Indonesia: Anak A. S. Sawitri, Putu C. D. Yuliyatni, Made D. Ariawan, Komang A. Kartika Sari, Raka Susanti, I Nyoman Sutarsa; Osong Public Health Res Perspect. 2021;12(3):158-168. Published online June 2, 2021; DOI: https://doi.org/10.24171/j.phrp.2020.0241

7,583 View
141 Download
1 Web of Science
1 Crossref

Graphical Abstract Abstract PDF

Objectives
The aim of this study was to compare the coverage of Japanese encephalitis (JE) immunization obtained from a recall survey and immunization registers at community health centers (CHCs) in Bali Province, Indonesia.
Methods
A population-based survey was conducted, and random 2-staged selection of clusters of sub-villages was performed. The sample consisted of households with children aged 9 months to 15 years old. Interviews were carried out with carers to recall JE immunization status. The recall immunization status was considered valid when name, date, and confirmation of immunization were available in an immunization register at a CHC. Descriptive analysis was performed. The completeness of the information within immunization registers at CHCs was assessed.
Results
The coverage of JE immunization obtained from the recall survey was 93.8% (95% confidence interval [CI], 92.8–94.9). It decreased to 74.9% (95% CI, 72.8–77.2) after being validated against immunization registers. The recall coverage of JE immunization was significantly higher than immunization register data suggested. This discrepancy varied from 6.5% to 36.4% across 6 districts; however, none of these districts achieved the recommended target coverage of 95%. The quality of immunization registers varied across CHCs.
Conclusion
The use of an immunization register may result in underestimating the true coverage of vaccination programs, and its utilization for measuring immunization coverage requires further consideration.

Citations

Citations to this article as recorded by

Japanese encephalitis in Bali, Indonesia: ecological and socio-cultural perspectives
I Made Kardena, Anak Agung Ayu Mirah Adi, Nyoman Mantik Astawa, Mark O’Dea, Michael Laurence, Shafi Sahibzada, Mieghan Bruce
International Journal of Veterinary Science and Me.2021; 9(1): 31. CrossRef

Data Fitting and Scenario Analysis of Vaccination in the 2014 Ebola Outbreak in Liberia: Zhifu Xie; Osong Public Health Res Perspect. 2019;10(3):187-201. Published online June 30, 2019; DOI: https://doi.org/10.24171/j.phrp.2019.10.3.10

7,229 View
201 Download
7 Crossref

Abstract PDF

Objectives

This study aimed to extend an epidemiological model (SEIHFR) to analyze epidemic trends, and evaluate intervention efficacy.

Methods

SEIHFR was modified to examine disease transmission dynamics after vaccination for the Ebola outbreak. Using existing data from Liberia, sensitivity analysis of various epidemic scenarios was used to inform the model structure, estimate the basic reproduction number ℜ₀ and investigate how the vaccination could effectively change the course of the epidemic.

Results

If a randomized mass vaccination strategy was adopted, vaccines would be administered prophylactically or as early as possible (depending on the availability of vaccines). An effective vaccination rate threshold for Liberia was estimated as 48.74% among susceptible individuals. If a ring vaccination strategy was adopted to control the spread of the Ebola virus, vaccines would be given to reduce the transmission rate improving the tracing rate of the contact persons of an infected individual.

Conclusion

The extended SEIHFR model predicted the total number of infected cases, number of deaths, number of recoveries, and duration of outbreaks among others with different levels of interventions such as vaccination rate. This model may be used to better understand the spread of Ebola and develop strategies that may achieve a disease-free state.

Citations

Citations to this article as recorded by

A secure data fitting scheme based on CKKS homomorphic encryption for medical IoT
Yunxuan Su, Xu An Wang, Weidong Du, Yu Ge, Kaiyang Zhao, Ming Lv
Journal of High Speed Networks.2023; 29(1): 41. CrossRef
Risk-averse multi-stage stochastic programming to optimizing vaccine allocation and treatment logistics for effective epidemic response
Xuecheng Yin, İ Esra Büyüktahtakın
IISE Transactions on Healthcare Systems Engineerin.2022; 12(1): 52. CrossRef
Model-based evaluation of the impact of prophylactic vaccination applied to Ebola epidemics in Sierra Leone and Democratic Republic of Congo
Ravi Potluri, Amit Kumar, Valérie Oriol-mathieu, Thierry Van Effelterre, Laurent Metz, Hitesh Bhandari
BMC Infectious Diseases.2022;[Epub] CrossRef
A hybrid simulation model to study the impact of combined interventions on Ebola epidemic
Peiyu Chen, Wenhui Fan, Xudong Guo, Constantinos Siettos
PLOS ONE.2021; 16(7): e0254044. CrossRef
Transmission dynamics of the COVID‐19 outbreak and effectiveness of government interventions: A data‐driven analysis
Yaqing Fang, Yiting Nie, Marshare Penny
Journal of Medical Virology.2020; 92(6): 645. CrossRef
Impact of prophylactic vaccination strategies on Ebola virus transmission: A modeling analysis
Ravi Potluri, Amit Kumar, Vikalp Maheshwari, Charlie Smith, Valerie Oriol Mathieu, Kerstin Luhn, Benoit Callendret, Hitesh Bhandari, Malaya Kumar Sahoo
PLOS ONE.2020; 15(4): e0230406. CrossRef
Modeling the 2014–2015 Ebola Virus Disease Outbreaks in Sierra Leone, Guinea, and Liberia with Effect of High- and Low-risk Susceptible Individuals
Qianying Lin, Salihu S. Musa, Shi Zhao, Daihai He
Bulletin of Mathematical Biology.2020;[Epub] CrossRef

Brief Report

Review of the Incidence of Japanese Encephalitis in Foreign-Born and Korean Nationals Living in the Republic of Korea, 2007–2016: Een-Suk Shin, Ok Park, In-Sik Kong; Osong Public Health Res Perspect. 2018;9(3):126-129. Published online June 30, 2018; DOI: https://doi.org/10.24171/j.phrp.2018.9.3.08

5,198 View
107 Download
5 Crossref

Abstract PDF

The Japanese encephalitis (JE) vaccine was introduced to the national immunization program in 1985, which has led to a dramatic decrease in the number of reported cases, but JE continues to occur in foreign nationals residing in or traveling to Korea. Although the incidence is low, this study demonstrated that more Koreans were infected with JE than foreign-born expatriates. The incidence rates of Korean-born nationals were between 0.01 and 0.08 cases per 100,000. In contrast, the incidence rates of foreign-born nationals ranged between 0 and 0.26 cases per 100,000. The incidence rates clearly showed that foreign-born expatriates were more at risk, which underscores the importance of vaccination. We recommend heightened surveillance among JE-susceptible individuals and promote vaccination among foreign-born nationals living in Korea.

Citations

Citations to this article as recorded by

Japanese encephalitis in a U.S. traveler returning from Vietnam, 2022
Zachary C. Janatpour, M. Andrew Boatwright, Sara M. Yousif, Maria-Fernanda Bonilla, Kelly A. Fitzpatrick, Susan L. Hills, Catherine F. Decker
Travel Medicine and Infectious Disease.2023; 52: 102536. CrossRef
Travel vaccines—priorities determined by incidence and impact
Robert Steffen, Lin H Chen, Peter A Leggat
Journal of Travel Medicine.2023;[Epub] CrossRef
Molecular Mechanism and Role of Japanese Encephalitis Virus Infection in Central Nervous System-Mediated Diseases
Pardeep Yadav, Pratik Chakraborty, Niraj Kumar Jha, Saikat Dewanjee, Abhimanyu Kumar Jha, Siva Prasad Panda, Prabhu Chandra Mishra, Abhijit Dey, Saurabh Kumar Jha
Viruses.2022; 14(12): 2686. CrossRef
Retention of neutralizing antibodies to Japanese encephalitis vaccine in age groups above fifteen years in Korea
Hee-Jung Lee, Hanul Choi, Ki Hoon Park, Yuyeon Jang, Young-jin Hong, Young Bong Kim
International Journal of Infectious Diseases.2020; 100: 53. CrossRef
Japanese Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices
Susan L. Hills, Emmanuel B. Walter, Robert L. Atmar, Marc Fischer, Emmanuel Walter, Robert L. Atmar, Elizabeth Barnett, Alan Barrett, Joseph A. Bocchini, Lin Chen, Eric Deussing, Doran Fink, Michael Holbrook, Myron Levin, Anthony Marfin, Cody Meissner, Ro
MMWR. Recommendations and Reports.2019; 68(2): 1. CrossRef

Original Article

Assessment of Intensive Vaccination and Antiviral Treatment in 2009 Influenza Pandemic in Korea: Chaeshin Chu, Sunmi Lee; Osong Public Health Res Perspect. 2015;6(1):47-51. Published online February 28, 2015; DOI: https://doi.org/10.1016/j.phrp.2014.11.007

3,125 View
19 Download
2 Crossref

Abstract PDF

Objectives
We characterized and assessed public health measures, including intensive vaccination and antiviral treatment, implemented during the 2009 influenza pandemic in the Republic of Korea.
Methods
A mathematical model for the 2009 influenza pandemic is formulated. The transmission rate, the vaccination rate, the antiviral treatment rate, and the hospitalized rate are estimated using the least-squares method for the 2009 data of the incidence curves of the infected, vaccinated, treated, and hospitalized.
Results
The cumulative number of infected cases has reduced significantly following the implementation of the intensive vaccination and antiviral treatment. In particular, the intensive vaccination was the most critical factor that prevented severe outbreak.
Conclusion
We have found that the total infected proportion would increase by approximately six times under the half of vaccination rates.

Citations

Citations to this article as recorded by

Modeling influenza transmission dynamics with media coverage data of the 2009 H1N1 outbreak in Korea
Yunhwan Kim, Ana Vivas Barber, Sunmi Lee, Roberto Barrio
PLOS ONE.2020; 15(6): e0232580. CrossRef
Doing Mathematics with Aftermath of Pandemic Influenza 2009
Hae-Wol Cho, Chaeshin Chu
Osong Public Health and Research Perspectives.2015; 6(1): 1. CrossRef

First
Prev
Page of 2
Next
Last

Search